ISSN 1662-4009 (online)

ey0020.1-7 | Congenital Hypothyroidism | ESPEYB20

1.7. Comorbidity in congenital hypothyroidism - A nationwide population-based cohort study

E Danner , J Jaaskelainen , L Niuro , H Huopio , H Niinikoski , L Viikari , J Kero , R Sund

Brief summary: Patients with congenital hypothyroidism have a higher rate of comorbidities in adult age (1). This nationwide population-based register study aimed at investigating the incidence of comorbidities present at birth or acquired during childhood in patients with congenital hypothyroidism and prescription of specific drugs (antidepressants, antipsychotics, medication for ADHS).The study analyzed data from n=438 full-term patients with ...

ey0019.4-6 | Important for clinical practice | ESPEYB19

4.6. Serum testosterone and oestradiol predict the growth response during puberty promoting treatment

H Huttunen , T Varimo , H Huopio , R Voutilainen , S Tenhola , PJ Miettinen , T Raivio , M Hero

Clinical Endocrinology. 2022; 96:220–226. PMID: 34596269Brief Summary: This randomized controlled trial evaluated the effects of testosterone and aromatase inhibitor treatment on anthropometric measures, and their correlation with estradiol and testosterone serum levels in boys with constitutional delay of growth and puberty (CDGP), to elucidate the respective roles of the two sex steroid hormones on growth during puberty. The results sugge...

ey0017.2-1 | Neonatal Hypoglycaemia | ESPEYB17

2.1. Clinical and genetic characterization of 153 patients with persistent or transient congenital hyperinsulinism

JME Mannisto , M Maria , J Raivo , T Kuulasmaa , T Otonkoski , H Huopio , Laakso

To read the full abstract: J Clin Endocrinol Metab. 2020 Apr 1;105(4). PMID: 32170320In congenital hyperinsulinism (CHI) there is dysregulation of insulin secretion that leads to persistent hypoglycaemia. Mutations in the ABCC8/KCNJ11 genes which encode the pancreatic KATP channels proteins (SUR1/KIR6.2 respectively) are the most common causes of CHI. Mutations ...

ey0017.7-1 | Clinical Guidance | ESPEYB17

7.1. Anti-Mullerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone

E Kohva , T Varimo , H Huopio , S Tenhola , R Voutilainen , J Toppari , PJ Miettinen , K Vaaralahti , J Viinamaki , JT Backman , M Hero , T Raivio

To read the full abstract: Human Reproduction (Oxford, England) vol. 35, 2 (2020): 257–264. doi: https://academic.oup.com/humrep/article/35/2/257/5709207. https://pubmed.ncbi.nlm.nih.gov/31958337/This randomized controlled trial compares treatment with peroral letrozole or intramuscular low-dose testosterone in ...

ey0016.7-15 | Treatment | ESPEYB16

7.15. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial

T Varimo , H Huopio , L Kariola , S Tenhola , R Voutilainen , J Toppari , S Toiviainen-Salo , E Hamalainen , MA Pulkkinen , M Laaperi , A Tarkkanen , K Vaaralahti , PJ Miettinen , M Hero , T Raivio

To read the full abstract: Lancet Child Adolesc Health. 2019 Feb;3(2):109–120This randomised, controlled, open-label trial at four paediatric centres in Finland evaluates aromatase inhibition with letrozole to induce puberty in boys with constitutional delay of growth and puberty.Treatment of delayed puberty aims to promote pubertal development ...